Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 11/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752641 | 1.00 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4CHRM2CHRM4 | |
| SCHEMBL16061721 | 0.98 | SLC6A3 (0.64) | SLC6A2SLC6A3SLC6A4CHRM2CHRM4 | |
| SCHEMBL6490853 | 0.88 | SLC6A3 (0.55) | SLC6A2SLC6A3SLC6A4CHRM2CHRM4 | |
| SCHEMBL6490857 | 0.88 | SLC6A3 (0.55) | SLC6A2SLC6A3SLC6A4CHRM2CHRM4 | |
| SCHEMBL6489548 | 0.86 | SLC6A3 (0.54) | SLC6A2SLC6A3SLC6A4CHRM2CHRM4 | |
| SCHEMBL21332404 | 0.85 | SLC6A3 (0.72) | SLC6A2SLC6A3SLC6A4CHRM5CHRM1 | |
| SCHEMBL1743636 | 0.84 | SLC6A3 (0.71) | SLC6A2SLC6A3SLC6A4CHRM5CHRM1 | |
| SCHEMBL16810267 | 0.83 | SLC6A3 (0.94) | SLC6A2SLC6A3SLC6A4CHRM2CHRM4 | |
| SCHEMBL4350867 | 0.82 | SLC6A3 (0.71) | SLC6A2SLC6A3SLC6A4CHRM2CHRM4 | |
| SCHEMBL6503781 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | BACHMANN STEPHAN | 2011-05-05 | — | — | US | disclosed |
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | BACHMANN STEPHAN | 2011-05-05 | — | — | US | disclosed |
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | BACHMANN STEPHAN | 2011-05-05 | — | — | US | disclosed |
| EP-2029541-B1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2009-12-30 | — | — | EP | disclosed |
| EP-2029541-B1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2009-12-30 | — | — | EP | disclosed |
| EP-2029541-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007113155-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC Β-ARYL OR HETEROARYL CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113155-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC Β-ARYL OR HETEROARYL CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | AHR, AR, CYP8B1 | SLC6A2 2378/4885SLC6A3 2693/4885SLC6A4 2893/4885 |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | AHR, CYP8B1, ADRA2C | SLC6A2 2332/4885SLC6A3 2337/4885SLC6A4 3061/4885 |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | AHR, CYP8B1, ADRA2C | SLC6A2 2332/4885SLC6A3 2337/4885SLC6A4 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.